459157-20-1

Basic information

• Product Name: 4-oxo-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-2- carboxylic acid
• Synonyms: 4-oxo-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-2- carboxylic acid;4-Oxo-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridine-2-carboxylicacid
• CAS NO: 459157-20-1
• Molecular Formula: C8H8N2O3
• Molecular Weight: 180.16072
• Mol File: 459157-20-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-oxo-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-2- carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-oxo-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-2- carboxylic acid(459157-20-1)
• EPA Substance Registry System: 4-oxo-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-2- carboxylic acid(459157-20-1)

Safety Data

• Hazardous Substances Data: 459157-20-1(Hazardous Substances Data)

Upstream product

• 37687-24-4 diethyl 1H-pyrazole-3,5-dicarboxylate 
• 459157-16-5 diethyl 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2,5-dicarboxylate 

Relevant articles and documents

Polyheterocyclic substituted pyrimidines or pyridylamine derivatives Composition and medical application thereof

The invention discloses a polycyclic substituted pyrimidine or pyridine amine derivative, and the structure is shown in a formula (I). The invention further discloses a pharmaceutically acceptable salt of the derivative, a solvate, a stereoisomer, a prodrug, a pharmaceutical composition and and an application thereof in medicine. The compounds of the present invention have significant adenosine A. 2A Receptor and/or adenosine A2B The receptor antagonism activity is very practical.

NEW COMPOUNDS AND METHODS

The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical compositions comprising the compounds of the invention, and to their use in the treatment or prevention of medical conditions in which inhibition of c-ABL is beneficial. (I)

Pyrazolopyrimidine derivatives

The present invention provides a compound of formula (I): where Q is a group of formula: These compounds inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably, the compounds are potent and selective inhibitors of the type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases and have utility therefore in a variety of therapeutic areas. In particular, the present compounds are of value for the curative or prophylactic treatment of mammalian sexual disorders.